E
IMDX

Ergoteles’s Insight Molecular Diagnostics IMDX Stock Holding History

Ergoteles’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,138
Closed -$33K – 1614
2022
Q4 		$33K Buy
5,138
+1,923
+60% +$21.2K ﹤0.01% 1329
2022
Q3 		$47K Sell
3,215
-8,392
-72% -$145K ﹤0.01% 1444
2022
Q2 		$209K Buy
+11,607
New +$264K 0.01% 1302
2021
Q4 		– Sell
-2,115
Closed -$151K – 1487
2021
Q3 		$151K Buy
2,115
+1,130
+115% +$104K 0.01% 1051
2021
Q2 		$113K Buy
+985
New +$96.2K ﹤0.01% 1381

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Ergoteles's IMDX Position: Q1 2023 in Review

Ergoteles sold out of Insight Molecular Diagnostics (IMDX) in Q1 2023, closing a stake of 5,138 shares — an estimated $33K sold.

Ergoteles first reported a position in IMDX in Q2 2021 and held it in 5 quarters. The position peaked at $209K in Q2 2022. 52 funds tracked by Wall St. Rank hold IMDX as of Q1 2023.

  • Ergoteles reported no remaining Insight Molecular Diagnostics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 5,138 Insight Molecular Diagnostics shares in Q1 2023, an estimated $33K.
  • Ergoteles first reported a position in Insight Molecular Diagnostics in Q2 2021 and held it in 5 quarters.
  • Ergoteles's Insight Molecular Diagnostics position peaked at $209K in Q2 2022.
  • 52 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.